



Announcement Summary

---

**Entity name**

BOTANIX PHARMACEUTICALS LTD

**Date of this announcement**

Friday December 01, 2023

**The +securities the subject of this notification are:**

Other

**Total number of +securities to be issued/transferred**

<b>ASX +security code</b>	<b>Security description</b>	<b>Total number of +securities to be issued/transferred</b>	<b>Issue date</b>
New class - code to be confirmed	Unquoted options exercisable at \$0.195 each, expiring on 1/12/25 (2 years from date of issue)	2,000,000	01/12/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

BOTANIX PHARMACEUTICALS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ABN

**Registration number**

70009109755

**1.3 ASX issuer code**

BOT

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

1/12/2023



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

Other

**Please specify**

2M options exercisable at \$0.195 each, expiring on 1/12/25 and included in the 27/11/23 Appendix 3B.

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

**New +securities**

**ASX +security code**

New class - code to be confirmed

**+Security description**

Unquoted options exercisable at \$0.195 each, expiring on 1/12/25 (2 years from date of issue)

**+Security type**

Options

**ISIN code**

**Date the +securities the subject of this notification were issued**

1/12/2023

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**

No

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**

Refer Appendix 3B - <https://announcements.asx.com.au/asxpdf/20231127/pdf/05xts6z9gj32sl.pdf> and placement ASX announcement - <https://announcements.asx.com.au/asxpdf/20231127/pdf/05xts0yb01q02j.pdf>

Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.19500000	1/12/2025

**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

Other

**Description**

BOT - fully paid ordinary shares.

**Any other information the entity wishes to provide about the +securities the subject of this notification**

2M options exercisable at \$0.195 each, expiring on 1/12/25 being 2 years from date of issue which were included in the Appendix 3B released to ASX on 27 November 2023.

**Please provide any further information needed to understand the circumstances in which you are notifying the**



**issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

The 2M options exercisable at \$0.195 each, expiring on 1/12/25 being 2 years from date of issue were included in the Appendix 3B released to ASX on 27 November 2023.

Issue details

---

**Number of +securities**

2,000,000

**Were the +securities issued for a cash consideration?**

Yes

**In what currency was the cash consideration being paid?**

AUD - Australian Dollar

**What was the issue price per +security?**

AUD 0.00001000

**Purpose of the issue**

To pay for services rendered

**Additional Details**

Part consideration of Lead Manager and Bookrunner services provided in relation to the Placement.



## Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:  
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

## 4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
BOT : ORDINARY FULLY PAID	1,437,298,487

## 4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
BOTAAD : PERFORMANCE RIGHTS	63,333,335
BOTAD : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	45,940,317
BOTAAC : OPTION EXPIRING 14-APR-2025 EX \$0.072	10,000,000
BOTAAB : OPTION EXPIRING 22-MAR-2025 EX \$0.094	4,000,000
BOTAAE : OPTION EXPIRING 13-MAR-2026 EX \$0.078	8,500,000
BOTA AF : OPTION EXPIRING 27-JUL-2025 EX \$0.18	6,000,000
BOTAAG : OPTION EXPIRING 12-SEP-2026 EX \$0.105	2,450,000
BOTAF : OPTION EXPIRING 7-OCT-2024 EX \$0.089	10,000,000
New class - code to be confirmed : Unquoted options exercisable at \$0.195 each, expiring on 1/12/25 (2 years from date of issue)	2,000,000



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

No

**5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

2,000,000 unquoted options.

**5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

No